COMPOUND WITH CONFIDENCE: PCCA Membership, $895/month.
Stay current on PCCA news and events, market trends, and all things compounding!
This Profile in Personalized Medicine highlights John C. Bellitti, RPh. He is the owner of HB Pharmacy in North Arlington, New Jersey. They have been a proud PCCA member since 1997.
We’ve expanded our Lipoderm family of permeation-enhancing bases and offer helpful tips, including which Lipoderm base works best for specific APIs, when compounding preparations for your patients.
Using social media to showcase your pharmacy delivers multiple benefits. Learn how to “get social” to market your pharmacy, gain insights and mark your brand’s footprint in the virtual world.
Read what we’re doing to ensure PCCA Formulas for compounding nonsterile preparations — specifically beyond-use dates — comply with USP Chapter 795 revisions.
Read more about how Canada and the U.S. regulators approach drug shortages, including duplicating approved drugs and the impacts of last winter’s drug shortages.
North America’s two largest countries, Canada and the U.S., have very different approaches to drug shortages. Read Part 1 of our two-part series to learn more about the distinctions between Health Canada and FDA regulations.
As we wind down National Arthritis Awareness Month, learn how compounders may help patients with the most common type of arthritis using compounded preparations and nutritional supplements.
This Profile in Personalized Medicine highlights Stacy Hightower. She is the lead marketer and compounding compliance officer for Las Colinas Pharmacy in Irving, Texas, owned by Jim and Jan Hrncir. They have been a proud PCCA member since 1990. Our new 2023 profiles ask pharmacy compounders how they incorporate PCCA’s Principles into their pharmacies.
Polycystic ovary syndrome (PCOS) is the most prevalent hormonal disorder affecting women of reproductive age across the globe and the CDC estimates PCOS may be one of the most common causes of infertility. Learn how to help patients with PCOS.
Genitourinary syndrome of menopause (GSM), also known as vulvovaginal atrophy, is common among menopausal women. Learn more about GSM, relevant hormones and the importance of choosing the right base for compounding preparations.